WO2007061554A3 - Dosage de derives de 4-aminopyridine pour le traitement des lesions du systeme nerveux central - Google Patents

Dosage de derives de 4-aminopyridine pour le traitement des lesions du systeme nerveux central Download PDF

Info

Publication number
WO2007061554A3
WO2007061554A3 PCT/US2006/041302 US2006041302W WO2007061554A3 WO 2007061554 A3 WO2007061554 A3 WO 2007061554A3 US 2006041302 W US2006041302 W US 2006041302W WO 2007061554 A3 WO2007061554 A3 WO 2007061554A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treatment
nerve tissue
compositions
dosage
Prior art date
Application number
PCT/US2006/041302
Other languages
English (en)
Other versions
WO2007061554A2 (fr
Inventor
Ryi Shi
Richard B Borgens
Daniel T Smith
Original Assignee
Purdue Research Foundation
Ryi Shi
Richard B Borgens
Daniel T Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Ryi Shi, Richard B Borgens, Daniel T Smith filed Critical Purdue Research Foundation
Publication of WO2007061554A2 publication Critical patent/WO2007061554A2/fr
Publication of WO2007061554A3 publication Critical patent/WO2007061554A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles pyridines, des compositions pharmaceutiques comprenant ces pyridines et l'utilisation de ces compositions dans le traitement des lésions du tissu nerveux mammifère, y compris mais non de façon limitative, une lésion de la moelle épinière. Dans un mode de réalisation, les composés, les compositions et les méthodes selon l'invention traitent une lésion du tissu nerveux mammifère en rétablissant le potentiel d'action ou la conduction nerveuse à travers une lésion du tissu nerveux. De manière significative, l'application in vivo de composés selon l'invention établit, sur la base d'un test de potentiel évoqué somesthésique, que les composés produisent à de faibles concentrations des effets plus durables qu'un traitement comparable à l'aide de l'agent 4-aminopyridine (4 AP) connu.
PCT/US2006/041302 2005-10-21 2006-10-23 Dosage de derives de 4-aminopyridine pour le traitement des lesions du systeme nerveux central WO2007061554A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72896005P 2005-10-21 2005-10-21
US60/728,960 2005-10-21

Publications (2)

Publication Number Publication Date
WO2007061554A2 WO2007061554A2 (fr) 2007-05-31
WO2007061554A3 true WO2007061554A3 (fr) 2007-10-11

Family

ID=38067700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041302 WO2007061554A2 (fr) 2005-10-21 2006-10-23 Dosage de derives de 4-aminopyridine pour le traitement des lesions du systeme nerveux central

Country Status (1)

Country Link
WO (1) WO2007061554A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (fr) 2015-02-20 2021-08-04 Incyte Corporation Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の塩
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US20040171587A1 (en) * 2002-12-06 2004-09-02 Borgens Richard B. Pyridines for treating injured mammalian nerve tissue

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US20040171587A1 (en) * 2002-12-06 2004-09-02 Borgens Richard B. Pyridines for treating injured mammalian nerve tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMITH D.T. ET AL.: "Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 1 August 2005 (2005-08-01), pages 908 - 917 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
WO2007061554A2 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2007061554A3 (fr) Dosage de derives de 4-aminopyridine pour le traitement des lesions du systeme nerveux central
WO2004052291A3 (fr) Pyridines destinees au traitement de tissus nerveux mammaliens leses
HUP0301920A2 (hu) P anyag receptor antagonista és magnézium vegyület kombinációját tartalmazó agy-, gerinc- és idegsérülés kezelésére szolgáló injekciós készítmény
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2008118718A3 (fr) Analogues de la 2-aminopyridine comme activateurs de la glucokinase
WO2007128817A3 (fr) Dérivé insulinique
WO2008054544A3 (fr) Procédé d'administration à travers la barrière hématoencéphalique
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
WO2005000217A3 (fr) Polytherapie permettant de traiter la dyslipidemie
TNSN07376A1 (en) Npy antagonists, preparation and use
WO2008095177A3 (fr) Procédés et dispositifs de traitement de tissu
WO2005042498A3 (fr) Agonistes des recepteurs de la capsicine
WO2006086693A3 (fr) Dispositifs medicaux
WO2007067519A3 (fr) Utilisation de neurotransmetteurs et de neuropeptides pour le traitement de maladies de secheresse oculaire et de conditions associees
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
WO2008157747A8 (fr) Utilisation d'inhibition d'exonucléase i dans des procédés de thérapie et de diagnostic de maladies neurodégénératives, de maladies oculaires et de troubles mitochondriaux
AU9543601A (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2007026028A3 (fr) Composition pharmaceutique contenant un chelateur du fer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06826478

Country of ref document: EP

Kind code of ref document: A2